The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | Lymphoma highlights at ASCO 2022
Stephen M. Ansell, MD, PhD, Mayo Clinic, Rochester, MN, gives his highlights in the field of lymphoma presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, including the progression-free survival (PFS) results of first-line brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) in pediatric patients. Prof. Ansell additionally talks on racial and socioeconomic disparities in lymphoma care, which can be especially pronounced with the advent of novel and expensive therapies. This interview took place at the ASCO 2022 Annual Meeting in Chicago, IL.
